ActoBiotics® are a new class of biopharmaceuticals based on our proprietary platform of engineered food-grade microbes (Lactococcus lactis) that express cytokines, enzymes, hormones, and monoclonal antibodies as therapeutics within the body.

The ActoBiotics® platform offers the unique ability to deliver biological effectors selectively to disease sites, such as the oral and gastrointestinal tract, enabling treatment not achievable through traditional approaches like injectable medicines and permitting ease of administration for patients.

With intervention focused at the site of pathology, this groundbreaking class of orally available biopharmaceuticals has the potential to facilitate targeted therapies against oral, gastrointestinal, metabolic, allergic and autoimmune diseases.

ActoBiotics Therapeutics has a strong R&D pipeline with the latest stage candidate in Phase 2b, two other candidates in clinical trials, and an extensive portfolio of candidates ready for clinical development across a number of indications.

Our new website is coming soon!